Jakarta, CNBC Indonesia – The majority of pharmaceutical issuers’ shares fell in the red zone at the beginning of today’s trading, Tuesday (7/6/2021). Investors seem to be taking profitprofit taking) after pharmaceutical stocks tend to soar recently.
The recent increase in pharmaceutical stocks was influenced by two main sentiments, namely, first, related to The Food and Drug Administration (BPOM) has just announced that it will soon conduct clinical trials on Ivermectin produced by Indofarma as a Covid-19 drug.
Then, the second sentiment that is driving the stocks is about the new daily case of Covid-19 in Indonesia which has continued to soar in the last month.
The following is the movement of pharmaceutical stocks, at 09.55 WIB:
-
Phapros (PEHA), shares -3.97%, to Rp 1,210, transaction Rp 337 million
-
Tempo Scan Pacific (TSPC), -2.62%, to Rp 1,485, transaction Rp 1 M
-
Indofarma (INAF), -2.39%, to Rp 3,270, transaction Rp 4 M
-
Kimia Farma (KAEF), -2.10%, to Rp 3,270, transaction Rp 10 M
-
Itama Ranoraya (IRRA), -0.91%, to Rp 2,180, transaction Rp 35 M
-
Kalbe Farma (KLBF) -0.72%, to Rp. 1,380, transaction of Rp. 6 M
-
Sido Muncul Herbal and Pharmaceutical Industry (SIDO) -0.67%, to Rp 745, transaction Rp 577 million
-
Pyridam Farma (PYFA), 0.00%, to Rp 1,000, transaction Rp 572 million
-
Merck (BRAND), +0.31%, to Rp. 3,200, transaction of Rp. 135 million
-
Darya-Varia Laboratoria (DVLA), +1.64%, to Rp 2,480, transaction Rp 16 million
-
SOHO Global Health (SOHO), +3.41%, to Rp 5,300, transaction Rp 93 million
According to the data above, of the 11 stocks observed, 7 stocks weakened, 1 stock was stagnant and the remaining 3 strengthened.
The shares of KAEF’s subsidiary, PEHA, became the most submerged, which was 3.97% to Rp 1,210/share. This correction occurred after PEHA shares recorded a strengthening rally for 3 consecutive days.
In a week, PEHA shares rose 3.81%, while in a month it jumped 5.13%.
In the second position, TSPC shares fell 2.30% to Rp 1,490/share, after yesterday’s increase of 1.33%. Despite weakening, in a week this stock rose 2.76%, while in the month minus 2.30%.
The shares of the two state-owned issuers, INAF and KAEF, also sank this morning. INAF shares fell 2.39%, while KAEF eroded 2.10%. In the last week, these two stocks rose 1.88% and 0.93% respectively. Meanwhile, in the past month INAF and KAEF’s shares soared 48.86% and 35.12%, respectively.
Meanwhile, SOHO shares, for example, rose 3.41%, after yesterday’s stagnation at Rp 5,125/share. DVLA shares also appreciated 1.64% to Rp 2,480/share, continuing a strong rally for 4 consecutive days.
As previously reported, Head of BPOM Penny Kusumastuti Lukito revealed that Ivermectin will soon be undergoing clinical trials as a Covid-19 drug. BPOM received Approval for Implementation of Clinical Trials (PPUK).
BPOM has previously issued a distribution permit for Ivermectin but as an anthelmintic.
“Clinical trials as a Covid-19 drug will soon be carried out. Thank you to the Minister of SOEs, Erick Thohir, who has concerns about access to handling Covid-19 drugs,” said Penny in her press conference with SOE Minister Erick Thohir, Monday (28/6).
In addition, Indofarma confirmed that it is producing the drug ivermectin which is used as a Covid-19 therapy. The number has reached 4 million tablets and has been started since 20 June.
“The production of 4 million started last Monday. Our capacity is quite large, taking a moderate figure of 4 million tablets per month,” said Indofarma President Director, Arief Pramuhanto, in Squawkbox, CNBC Indonesia, Wednesday (23/6).
Meanwhile, on Monday (5/7), the Minister of State-Owned Enterprises (BUMN) Erick Thohir checking the availability of ivermectin at three pharmacies owned by Kimia Farma in Jakarta. On that occasion, Erick criticized the surge in the price of drugs used for prevention and treatment of Covid-19 in recent times.
“The prices on the market are currently very painful for the people in the midst of high demand and the number of Covid-19 patients who have died. Therefore, I have ordered Kimia Farma to immediately market ivermectin at prices according to the regulations of the Ministry of Health and BPOM and can only be obtained with a doctor’s prescription,” said Erick.
He also ordered Kimia Farma to carry out internal supervision in SOEs and promised to take firm action indiscriminately and condemn any individual Kimia Farma, Indofarma or state-owned companies who hoard for personal gain.
The country’s Covid-19 cases do not seem to have subsided, and continue to break record highs. On Saturday (3/7) Covid-19 cases in the country reached the highest number of 27,913 cases. Meanwhile, the next day, new cases still did not show a decline, still at 27,000.
On Monday (5/7), the Ministry of Health recorded the addition of 29,745 Covid-19 cases and touched a record high. With this, the total number of Covid-19 cases in the country has reached 2,313,829.
Meanwhile, 14,416 people have recovered from this disease, bringing the total to 1,942,690. Meanwhile, the number of deaths due to Covid-19 also continued to increase by 558, bringing the total to 61,140 people. The increase in the number of deaths is also a record high.
CNBC INDONESIA RESEARCH TEAM
(adf/adf)
– .
